Clinical and Translational Medicine (May 2023)
Correction to: BCL2L2 loss renders ‐14q renal cancer dependent on BCL2L1 that mediates resistance to tyrosine kinase inhibitors
Abstract
No abstracts available.
Clinical and Translational Medicine (May 2023)